MENU

BMY Stock Bristol-Myers Squibb (BMY, $47.85) was a top weekly gainer, with a +6.76% jump

A.I.dvisor
at Tickeron.com
Loading...
BMY - Bristol-Myers Squibb Co
Tickeron

Loading...

Price: $47.85
Daily change: +$1.3 (+2.79%)
Daily volume: 10.1M
Weekly price change: +$3.03 (+6.76%)
Capitalization: $97.4B
Industry: Pharmaceuticals: Major
Bristol-Myers Squibb (BMY, $47.85) was one of the top gainers this week, climbing to $47.85 per share. A.I.dvisor analyzed 61 stocks in the Pharmaceuticals: Major Industry over the last week and discovered that of them (8) trended up while of them (1) trended down.

BMY's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for BMY moved out of oversold territory on August 01, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 13, 2025. You may want to consider a long position or call options on BMY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BMY just turned positive on August 12, 2025. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

BMY moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 205 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for BMY crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.627) is normal, around the industry mean (9.432). P/E Ratio (19.353) is within average values for comparable stocks, (23.655). Projected Growth (PEG Ratio) (1.120) is also within normal values, averaging (1.875). BMY has a moderately high Dividend Yield (0.051) as compared to the industry average of (0.027). P/S Ratio (2.055) is also within normal values, averaging (3.385).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

View a ticker or compare two or three
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BMY showed earnings on July 31, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com